Selachyl alcohol
Based on 1 Customer Validation
Selachyl alcohol is an orally active antihypertensive agent. Selachyl alcohol has similar activities with antihypertensive neutral renomedullary lipid (ANRL). Selachyl alcohol is an alkylglycerol compound in shark liver oil mixture with properties that reduce lung metastasis. Selachyl alcohol can be used for cardiovascular disease research.
For research use only. We do not sell to patients.
- Purity : 99.51%
- CAS No.: 593-31-7
- Formula: C21H42O3
- Molecular Weight:342.56
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All Endogenous Metabolite Isoforms
More
Biological Activity
Description
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley rats with hypertension[1]
-
Dosage:5 and 10 mg (oral gavage); 1 mg (i.v.)
-
Administration:Oral gavage, 5 and 10 mg, 10 occasions; intravenous injection, 1 mg, once
-
Result:Induced blood pressure drops slowly about 60 mm Hg and remains for 20 minutes. Effectively reduced blood pressure by gastrointestinal tract.
Chemical Information
-
CAS No. 593-31-7
-
Appearance Oil
-
Molecular Weight 342.56
-
Formula C21H42O3
-
Color Colorless to off-white
-
SMILES
OCC(O)COCCCCCCCC/C=C\CCCCCCCC
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (291.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Tail-Vein Experimental Metastasis Xenograft
Tail-vein experimental metastasis xenograft models assess the ability of injected tumor cells to survive circulation, arrest in vascular beds, extravasate, and colonize distant organs, most commonly lung after lateral tail-vein injection; this model bypasses primary-tumor formation, local invasion, and intravasation, so the readout reflects late metastatic colonization rather than the full metastatic cascade. The main readouts are metastatic burden measured by bioluminescence imaging, gross metastatic nodules, histology, organ weight, survival, or ex vivo tumor-cell quantification; luciferase-labeled tumor cells permit longitudinal noninvasive monitoring, while histology confirms organ colonization and tissue localization.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
-
Data Sheet (265 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Muirhead EE, et al. Selachyl alcohol as an oral antihypertensive agent: a preliminary note. Am J Med Sci. 1987 Nov;294(5):384-7. [Content Brief]
[2]. Momha R, et al. Anti-Angiogenic and Cytotoxicity Effects of Selachyl Alcohol Analogues. Anticancer Agents Med Chem. 2022;22(10):1913-1920. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9192 mL | 14.5960 mL | 29.1920 mL | 72.9799 mL |
| 5 mM | 0.5838 mL | 2.9192 mL | 5.8384 mL | 14.5960 mL | |
| 10 mM | 0.2919 mL | 1.4596 mL | 2.9192 mL | 7.2980 mL | |
| 15 mM | 0.1946 mL | 0.9731 mL | 1.9461 mL | 4.8653 mL | |
| 20 mM | 0.1460 mL | 0.7298 mL | 1.4596 mL | 3.6490 mL | |
| 25 mM | 0.1168 mL | 0.5838 mL | 1.1677 mL | 2.9192 mL | |
| 30 mM | 0.0973 mL | 0.4865 mL | 0.9731 mL | 2.4327 mL | |
| 40 mM | 0.0730 mL | 0.3649 mL | 0.7298 mL | 1.8245 mL | |
| 50 mM | 0.0584 mL | 0.2919 mL | 0.5838 mL | 1.4596 mL | |
| 60 mM | 0.0487 mL | 0.2433 mL | 0.4865 mL | 1.2163 mL | |
| 80 mM | 0.0365 mL | 0.1824 mL | 0.3649 mL | 0.9122 mL | |
| 100 mM | 0.0292 mL | 0.1460 mL | 0.2919 mL | 0.7298 mL |
Selachyl alcohol Related Classifications
HY-152899 Related Classifications
Powered by Bioz